Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Torimoto, Keiichi ^a   Okada, Yosuke ^a   Mori, Hiroko ^a   Hajime, Maiko ^a   Tanaka, Kenichi ^a   Kurozumi, Akira ^a   Narisawa, Manabu ^a   Yamamoto, Sunao ^a   Arao, Tadashi ^a   Matsuoka, Hirofumi ^b   Inokuchi, Nobuo ^c   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Matsuoka Clinic   (Japan)

^c Inokuchi Clinic   (Japan)

Author keywords

Ezetimibe; Hypercholesterolemia; Rosuvastatin; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; ROSUVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84884341099     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-137     Document Type: Article

References (38)

1. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Sarwar N, Gao P, Emerging Risk Factors Collaboration, et al. Lancet 2010 375 2215 2222
2. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan diabetes complications study (JDCS). Sone H, Tanaka S, Tanaka S, et al. J Clin Endocrinol Metab 2011 96 3448 3456
3. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Tenenbaum A, Fisman EZ, Motro M, Adler Y, Cardiovasc Diabetol 2006 5 20
4. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan atherosclerosis society guideline for diagnosis and treatment of hyperlipidemia in Japanese adults: a study of the Japan lipid assessment program (J-LAP). Teramoto T, Kashiwagi A, Mabuchi H, Curr Ther Res Clin Exp 2005 66 80 95
5. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Altmann SW, Davis HR Jr, Zhu LJ, et al. Science 2004 303 1201 1204 (Pubitemid 38233587)
6. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Morrone D, Weintraub WS, Toth PP, et al. Atherosclerosis 2012 223 251 261
7. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Baigent C, Landray MJ, Reith C, SHARP Investigators, et al. Lancet 2011 377 2181 2192
8. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. Arai H, Hiro T, Kimura T, et al. J Atheroscler Thromb 2010 17 1096 1107
9. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Takayama T, Hiro T, Yamagishi M, et al. Circ J 2009 73 2110 2117
10. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for atherosclerosis regression treatment (JART) study. Nohara R, Daida H, Hata M, Justification for Atherosclerosis Regression Treatment (JART) Investigators, et al. Circ J 2012 76 221 229
11. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: the circulatory risk in communities study (CIRCS). Imano H, Noda H, Kitamura A, et al. Prev Med 2011 52 381 386
12. Development of a homogeneous assay for measurement of small dense LDL cholesterol. Ito Y, Fujimura M, Ohta M, Hirano T, Clin Chem 2011 57 57 65
13. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Seino Y, Nanjo K, Tajima N, et al. Diabetol Int 2010 1 2 20
14. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Bays HE, Davidson MH, Massaad R, et al. Am J Cardiol 2011 108 523 530
15. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Gylling H, Int J Pract 2004 58 859 866 (Pubitemid 39462208)
16. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Barrios V, Amabile N, Paganelli F, et al. Int J Clin Pract 2005 59 1377 1386 (Pubitemid 43922623)
17. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM, Cardiovasc Diabetol 2010 9 20
18. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Ravid Z, Bendayan M, Delvin E, et al. Am J Physiol Gastrointest Liver Physiol 2008 295 873 G885
19. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Lally SE, Owens D, Tomkin GH, Diabetologia 2007 50 217 219 (Pubitemid 46035872)
20. Low-density lipoprotein subclass patterns and risk of myocardial infarction. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM, JAMA 1988 260 1917 1921
21. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Feingold KR, Grunfeld C, Pang M, et al. Arterioscler Thromb 1992 12 1496 1502
22. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Winkler K, Jacob S, Müller-Schewe T, et al. Atherosclerosis 2012 220 189 193
23. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Holvoet P, Vanhaecke J, Janssens S, et al. Circulation 1998 98 1487 1494 (Pubitemid 28481664)
24. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL, N Engl J Med 1989 320 915 924 (Pubitemid 19101597)
25. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. Itabe H, Ueda M, J Atheroscler Thromb 2007 14 1 11
26. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. Uemura Y, Watarai M, Ishii H, et al. J Cardiol 2012 59 50 56
27. Remnant lipoproteins as strong key particles to atherogenesis. Fujioka Y, Ishikawa Y, J Atheroscler Thromb 2009 16 145 154
28. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Watanabe N, Taniguchi T, Taketoh H, et al. Diabetes Care 1999 22 152 156 (Pubitemid 29028313)
29. Increased cholesterol concentration in intermediate density lipoprotein fraction of normolipidemic non-insulin-dependent diabetics. Kasama T, Yoshino G, Iwatani I, et al. Atherosclerosis 1987 63 263 266 (Pubitemid 17232760)
30. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Nakamura T, Hirano M, Kitta Y, et al. J Cardiol 2012 60 12 17
31. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Eur J Clin Invest 2009 39 689 698
32. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Labonté ED, Camarota LM, Rojas JC, et al. Am J Physiol Gastrointest Liver Physiol 2008 295 776 783
33. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. J Atheroscler Thromb 2010 17 914 924
34. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. Galeano NF, Milne R, Marcel YL, et al. J Biol Chem 1994 269 511 519 (Pubitemid 24026689)
35. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR, J Lipid Res 2006 47 2575 2580 (Pubitemid 44936118)
36. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. Deushi M, Nomura M, Kawakami A, et al. FEBS Lett 2007 581 5664 5670 (Pubitemid 350179776)
37. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I, Diabetes Res Clin Pract 2013 100 46 52
38. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Muraoka T, Aoki K, Iwasaki T, et al. Metabolism 2011 60 617 628